Atomoxetine Hydrochloride

Atomoxetine Hydrochloride is commonly used to treat attention deficit and hyperactivity disorder (ADHD). Atomoxetine Hydrochloride can help to increase attention, as well as decrease impulsiveness and hyperactivity. Atomoxetine Hydrochloride works as a selective norepinephrine reuptake inhibitor. Atomoxetine Hydrochloride may act by boosting norepinephrine, a naturally occurring chemical in the brain.

Atomoxetine Hydrochloride is a selective norepinephrine reuptake inhibitor indicated for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD).

Atomoxetine is known to be a potent and selective inhibitor of the norepinephrine transporter (NET),2 which prevents cellular reuptake of norepinephrine throughout the brain, which is thought to improve the symptoms of ADHD. More recently, positron emission tomography (PET) imaging studies in rhesus monkeys have shown that atomoxetine also binds to the serotonin transporter (SERT),9 and blocks the N-methyl-d-aspartate (NMDA) receptor,10 indicating a role for the glutamatergic system in the pathophysiology of ADHD.

Adult Dose: As advised by the physician. Child Dose: pharmacokinetics of atomoxetine in children less than 6. Renal Dose: It should be used with caution in patients with kidney disease. Dose adjustment may be needed. Please consult your physician.

Take Atomoxetine Hydrochloride orally after your meal.

Take Atomoxetine Hydrochloride as soon as you remember .If it is almost time for your next dose, skip the missed dose and take next dose at the regular time. Do not take two doses at the same time.

Symptoms of over dose may include: • Blood pressure increased • Heart rate increased. • Abdominal pain. • Ejaculation disorder. • Tachycardia. • lethargy. • Rash. • peripheral coldness.

Suicidal Ideation and Behaviour: Suicidal ideation (suicidal thoughts) was statistically more frequently observed in clinical trials among children and adolescents treated with Atomoxetine (5/1357; [0.37%]) compared to those treated with placebo (0/851; [0%]). There was one report of suicidal behaviour in a patient in this age group treated with Atomoxetine compared with no reports in patients treated with a placebo. Aggressive Behaviour or Hostility: Although there is no conclusive evidence that Atomoxetine causes aggressive behaviour or hostility, during clinical trials these events were more frequently observed in children and adolescents treated with Atomoxetine compared to those receiving placebo (overall risk ratio of 1.33- not statistically significant). Seizures: The pre-clinical and clinical trial data for Atomoxetine do not suggest that Atomoxetine is proconvulsive. However, seizures have been very rarely reported in post-marketing spontaneous reports. Atomoxetine should be used with caution in patients with a history of seizures. Cardiovascular Effects: Atomoxetine can affect heart rate and blood pressure. It is recommended that the heart rate and blood pressure be measured before treatment is started and periodically during treatment to detect possible clinically important increases.

Not recommended for patients who have a known hypersensitivity to salicylates or to any other component of the formulation.

Atomoxetine may inhibit Abacavir excretion, resulting in a greater serum level. Atomoxetine metabolism can be improved when coupled with Abatacept. Atomoxetine metabolism can be inhibited when taken with Abiraterone. Acebutolol can reduce Atomoxetine metabolism.Atomoxetine with Aceclofenac may enhance the risk or severity of hypertension.